TriangleAnti-CD40 Agonist Monoclonal… (NCT05231122)
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 trial for Ovarian Clear Cell Adenocarcinoma (NCT05231122). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with recurrent serous, endometrioid, or clear-cell ovarian, fallopian-tube, or primary peritoneal cancer. BRCA status must be known; up to four prior treatment lines are allowed. Primary platinum-refractory disease and progression on checkpoint blockade are excluded.
The idea: patients receive intravenous pembrolizumab and bevacizumab, with or without CDX-1140, every three weeks. CDX-1140 activates CD40 on immune cells. Researchers compare safety and tumor response; tissue sampling has specified exceptions.
This phase 2 study plans 80 patients. Emese Zsiros leads at Roswell Park; Buffalo and Houston have recruiting sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.